Everolimus (RAD001) can be an orally administered agent that inhibits the mammalian focus on of rapamycin serine-threonine kinase. therapy after failing of prior first-line sunitinib. solid course=”kwd-title” Keywords: everolimus, kidney tumor, mTOR, renal cell carcinoma Launch Renal cell carcinoma (RCC) may be the seventh leading tumor among men as well as the tenth among ladies… Continue reading Everolimus (RAD001) can be an orally administered agent that inhibits the